Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (the Company) has announced a revision of its annual cap under the “Fosun International Mutual Supply Framework Agreement.” The original cap for services provided by Fosun International and/or its associates to the Company in 2025, initially set at RMB70 million, is now raised to RMB90 million. The revised cap addresses expected additional service transactions in the last quarter of 2025, driven by the Company’s further business development needs.

The agreement spans from 1 January 2025 to 31 December 2025 and covers areas such as medical products, medical services, and consulting services. According to the latest data disclosed for the nine months ended 30 September 2025, the actual amount used under the services portion reached approximately RMB59.14 million, representing 84% of the original RMB70 million cap.

Management has confirmed that the revision complies with Chapter 14A of the Hong Kong Listing Rules. Since the highest applicable percentage ratio (other than the profits ratio) is more than 0.1% but less than 5%, the revised cap is subject to reporting, announcement, and annual review requirements yet remains exempt from independent shareholders’ approval. The board of directors, excluding interested directors who abstained from voting, considers the revised annual cap to be fair and reasonable and in line with the Company’s ordinary business activities.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a leading healthcare group in the People’s Republic of China, engaging in pharmaceutical manufacturing, medical devices and diagnosis, healthcare services, and pharmaceutical distribution and retail. This revision was approved on 28 October 2025, and all other key terms of the framework agreement remain unchanged.